REVELICE - Startup: immuneAdvice

Medical needs

Immunotherapies have revolutionized cancer treatment in recent years, but their success is severely limited due to the as yet unpredictable individual response. The high proportion of unsuccessful immunotherapies causes not only a loss of time for patients, but also enormous additional costs for the healthcare system. In an aging society with further increasing numbers of cancer patients and new immunotherapies, stratification of patients is essential.

Our technology

immuneAdvice develops novel tracer molecules (ICE-Ts) based on single domain antibodies (VHHs) for the detection of immune cell populations in non-invasive clinical imaging. ICE-Ts visualize with spatial and temporal resolution the dynamic distribution of immune cells and their activation state, making the response to immunotherapy individually determinable. Our goal is to establish therapy-decisive diagnostics that predict the efficacy of current and future immunotherapies and evaluate them concomitantly with therapy.

immuneAdvice is funded by EXIST - Existenzgründungen aus der Wissenschaft to complete preclinical development of the first ICE-T. A first study in humans is planned to start in 2025.